A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
Major depressive disorder.
Antidepressant drug-free.
Schizophrenia
Mania
Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
Obsessive-compulsive disorder
National Science and Technology Council, Taiwan
Lead sponsor
Ministry of Science and Technology, Taiwan
Sponsor institution
Fondation FondaMental
Collaborator
Fondation pour la Recherche Médicale (FRM)
Collaborator
Ministry of Science and Technology, Taiwan
Collaborator